schliessen

Filtern

 

Bibliotheken

Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study

Highlights • We evaluate a Phase III production lot of a candidate dengue vaccine (CYD-TDV). • CYD-TDV demonstrates a satisfactory safety profile in children. • CYD-TDV demonstrates a balanced immune response against all dengue virus serotypes.

Journal Title: Vaccine 2013, Vol.31 (49), p.5814-5821
Main Author: HSS, Amar-Singh
Other Authors: Koh, Mia-Tuang , Tan, Kah Kee , Chan, Lee Gaik , Zhou, Lynn , Bouckenooghe, Alain , Crevat, Denis , Hutagalung, Yanee
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Kidlington: Elsevier Ltd
ID: ISSN: 0264-410X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1459973589
title: Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study
format: Article
creator:
  • HSS, Amar-Singh
  • Koh, Mia-Tuang
  • Tan, Kah Kee
  • Chan, Lee Gaik
  • Zhou, Lynn
  • Bouckenooghe, Alain
  • Crevat, Denis
  • Hutagalung, Yanee
subjects:
  • Allergy and Immunology
  • Antibodies, Neutralizing - blood
  • Antibodies, Viral - blood
  • Applied microbiology
  • Arboviroses
  • Biological and medical sciences
  • Child
  • Child, Preschool
  • Cross Protection
  • Dengue
  • Dengue - prevention & control
  • Dengue fevers
  • Dengue Vaccines - adverse effects
  • Dengue Vaccines - therapeutic use
  • Environmental
  • Female
  • Fundamental and applied biological sciences. Psychology
  • Human viral diseases
  • Humans
  • Immunity, Humoral
  • Immunization Schedule
  • Immunogenicity
  • Immunology
  • Infectious Diseases
  • Malaysia
  • Male
  • Medical sciences
  • Microbiology
  • Microbiology(all)
  • Molecular Medicine
  • Occupational Health
  • Paediatric population
  • Public Health
  • Safety
  • Single-Blind Method
  • Suggestions dengue
  • Tropical viral diseases
  • Vaccination - adverse effects
  • Vaccine
  • Vaccines
  • Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
  • veterinary(all)
  • Viral diseases
ispartof: Vaccine, 2013, Vol.31 (49), p.5814-5821
description: Highlights • We evaluate a Phase III production lot of a candidate dengue vaccine (CYD-TDV). • CYD-TDV demonstrates a satisfactory safety profile in children. • CYD-TDV demonstrates a balanced immune response against all dengue virus serotypes.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.510121
LOCALfalse
PrimoNMBib
record
control
sourceidgale_opena
recordidTN_cdi_proquest_miscellaneous_1459973589
sourceformatXML
sourcesystemPC
galeidA352054896
sourcerecordidA352054896
originalsourceidFETCH-LOGICAL-1735t-9fedf7686e344336891e97e3bfa6316defe16353ffbc2d1ff2aadf0a35a7e00e3
addsrcrecordideNqNU8uKFDEULURxxtFPULIRXNhtUqnUQ0EZBh8NIwqj4C7cSm6606aStlI1UK78B_d-nF9iim5HmM1ILS51OOfm5p6TLHvI6JJRVj7bLi9BKetxmVPGE7ZM5VZ2zOqKL3LB6tvZMc3LYlEw-uUouxfjllIqOGvuZkd5wbgQFT_Ofl2AwWEi4DWxXTf6sEZvlU1QMATIgEMPl-DQD0SjX49IDucS68kGwQ2biaiNdbpHT2CNmuS_f_xkjEwIfZxZ78HBFC08J6ekTweFzn5H_ZTsHChsw0IFP_TBuRn7uIGIZLVakTiMerqf3THgIj441JPs85vXn87eLc4_vF2dnZ4vWMXFsGgMalOVdYm8KDgv64ZhUyFvDZSclRoNspILbkyrcs2MyQG0ocAFVEgp8pNste8bdujB9ih3ve2gn2QAK7XHQbZpsPQn85abqjG0Aq55wfNStFRQYCVrlMkFpF5P9r12ffg2YhxkZ6NC58BjGKNkhWiaNHbdJOpyT12nDUvrTUjbVunT2Nm0FjQ24ae85nnNku6_BSKnoqibMgnEXqD6EGOP5upijMo5SHIrD4bKOUgznErSPTpcYmw71Feqv8lJhMcHAkQFziRjlY3_eDVltBIz78W1AVK4YLCz52DdjWO82qsxmX9psZdRWfQKdfJIDVIHe2OHl9c6KGdTwsF9xQnjNoy9T8mSTMZcUnkxv5n5yTCe1KWg_A8MkRLi
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1459973589
display
typearticle
titleSafety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study
sourceAlma/SFX Local Collection
creatorHSS, Amar-Singh ; Koh, Mia-Tuang ; Tan, Kah Kee ; Chan, Lee Gaik ; Zhou, Lynn ; Bouckenooghe, Alain ; Crevat, Denis ; Hutagalung, Yanee
creatorcontribHSS, Amar-Singh ; Koh, Mia-Tuang ; Tan, Kah Kee ; Chan, Lee Gaik ; Zhou, Lynn ; Bouckenooghe, Alain ; Crevat, Denis ; Hutagalung, Yanee
descriptionHighlights • We evaluate a Phase III production lot of a candidate dengue vaccine (CYD-TDV). • CYD-TDV demonstrates a satisfactory safety profile in children. • CYD-TDV demonstrates a balanced immune response against all dengue virus serotypes.
identifier
0ISSN: 0264-410X
1EISSN: 1873-2518
2DOI: 10.1016/j.vaccine.2013.10.013
3PMID: 24135573
4CODEN: VACCDE
languageeng
publisherKidlington: Elsevier Ltd
subjectAllergy and Immunology ; Antibodies, Neutralizing - blood ; Antibodies, Viral - blood ; Applied microbiology ; Arboviroses ; Biological and medical sciences ; Child ; Child, Preschool ; Cross Protection ; Dengue ; Dengue - prevention & control ; Dengue fevers ; Dengue Vaccines - adverse effects ; Dengue Vaccines - therapeutic use ; Environmental ; Female ; Fundamental and applied biological sciences. Psychology ; Human viral diseases ; Humans ; Immunity, Humoral ; Immunization Schedule ; Immunogenicity ; Immunology ; Infectious Diseases ; Malaysia ; Male ; Medical sciences ; Microbiology ; Microbiology(all) ; Molecular Medicine ; Occupational Health ; Paediatric population ; Public Health ; Safety ; Single-Blind Method ; Suggestions dengue ; Tropical viral diseases ; Vaccination - adverse effects ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; veterinary(all) ; Viral diseases
ispartofVaccine, 2013, Vol.31 (49), p.5814-5821
rights
0The Authors
12013 The Authors
22015 INIST-CNRS
3Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.
4COPYRIGHT 2013 Elsevier B.V.
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1735t-9fedf7686e344336891e97e3bfa6316defe16353ffbc2d1ff2aadf0a35a7e00e3
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28010753$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24135573$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0HSS, Amar-Singh
1Koh, Mia-Tuang
2Tan, Kah Kee
3Chan, Lee Gaik
4Zhou, Lynn
5Bouckenooghe, Alain
6Crevat, Denis
7Hutagalung, Yanee
title
0Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study
1Vaccine
addtitleVaccine
descriptionHighlights • We evaluate a Phase III production lot of a candidate dengue vaccine (CYD-TDV). • CYD-TDV demonstrates a satisfactory safety profile in children. • CYD-TDV demonstrates a balanced immune response against all dengue virus serotypes.
subject
0Allergy and Immunology
1Antibodies, Neutralizing - blood
2Antibodies, Viral - blood
3Applied microbiology
4Arboviroses
5Biological and medical sciences
6Child
7Child, Preschool
8Cross Protection
9Dengue
10Dengue - prevention & control
11Dengue fevers
12Dengue Vaccines - adverse effects
13Dengue Vaccines - therapeutic use
14Environmental
15Female
16Fundamental and applied biological sciences. Psychology
17Human viral diseases
18Humans
19Immunity, Humoral
20Immunization Schedule
21Immunogenicity
22Immunology
23Infectious Diseases
24Malaysia
25Male
26Medical sciences
27Microbiology
28Microbiology(all)
29Molecular Medicine
30Occupational Health
31Paediatric population
32Public Health
33Safety
34Single-Blind Method
35Suggestions dengue
36Tropical viral diseases
37Vaccination - adverse effects
38Vaccine
39Vaccines
40Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
41veterinary(all)
42Viral diseases
issn
00264-410X
11873-2518
fulltexttrue
rsrctypearticle
creationdate2013
recordtypearticle
recordideNqNU8uKFDEULURxxtFPULIRXNhtUqnUQ0EZBh8NIwqj4C7cSm6606aStlI1UK78B_d-nF9iim5HmM1ILS51OOfm5p6TLHvI6JJRVj7bLi9BKetxmVPGE7ZM5VZ2zOqKL3LB6tvZMc3LYlEw-uUouxfjllIqOGvuZkd5wbgQFT_Ofl2AwWEi4DWxXTf6sEZvlU1QMATIgEMPl-DQD0SjX49IDucS68kGwQ2biaiNdbpHT2CNmuS_f_xkjEwIfZxZ78HBFC08J6ekTweFzn5H_ZTsHChsw0IFP_TBuRn7uIGIZLVakTiMerqf3THgIj441JPs85vXn87eLc4_vF2dnZ4vWMXFsGgMalOVdYm8KDgv64ZhUyFvDZSclRoNspILbkyrcs2MyQG0ocAFVEgp8pNste8bdujB9ih3ve2gn2QAK7XHQbZpsPQn85abqjG0Aq55wfNStFRQYCVrlMkFpF5P9r12ffg2YhxkZ6NC58BjGKNkhWiaNHbdJOpyT12nDUvrTUjbVunT2Nm0FjQ24ae85nnNku6_BSKnoqibMgnEXqD6EGOP5upijMo5SHIrD4bKOUgznErSPTpcYmw71Feqv8lJhMcHAkQFziRjlY3_eDVltBIz78W1AVK4YLCz52DdjWO82qsxmX9psZdRWfQKdfJIDVIHe2OHl9c6KGdTwsF9xQnjNoy9T8mSTMZcUnkxv5n5yTCe1KWg_A8MkRLi
startdate2013
enddate2013
creator
0HSS, Amar-Singh
1Koh, Mia-Tuang
2Tan, Kah Kee
3Chan, Lee Gaik
4Zhou, Lynn
5Bouckenooghe, Alain
6Crevat, Denis
7Hutagalung, Yanee
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier BV
scope
06I.
1AAFTH
2IQODW
3CGR
4CUY
5CVF
6ECM
7EIF
8NPM
9AAYXX
10CITATION
11BSHEE
127X8
13BOBZL
14CLFQK
sort
creationdate2013
titleSafety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study
authorHSS, Amar-Singh ; Koh, Mia-Tuang ; Tan, Kah Kee ; Chan, Lee Gaik ; Zhou, Lynn ; Bouckenooghe, Alain ; Crevat, Denis ; Hutagalung, Yanee
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1735t-9fedf7686e344336891e97e3bfa6316defe16353ffbc2d1ff2aadf0a35a7e00e3
rsrctypearticles
prefilterarticles
languageeng
creationdate2013
topic
0Allergy and Immunology
1Antibodies, Neutralizing - blood
2Antibodies, Viral - blood
3Applied microbiology
4Arboviroses
5Biological and medical sciences
6Child
7Child, Preschool
8Cross Protection
9Dengue
10Dengue - prevention & control
11Dengue fevers
12Dengue Vaccines - adverse effects
13Dengue Vaccines - therapeutic use
14Environmental
15Female
16Fundamental and applied biological sciences. Psychology
17Human viral diseases
18Humans
19Immunity, Humoral
20Immunization Schedule
21Immunogenicity
22Immunology
23Infectious Diseases
24Malaysia
25Male
26Medical sciences
27Microbiology
28Microbiology(all)
29Molecular Medicine
30Occupational Health
31Paediatric population
32Public Health
33Safety
34Single-Blind Method
35Suggestions dengue
36Tropical viral diseases
37Vaccination - adverse effects
38Vaccine
39Vaccines
40Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
41veterinary(all)
42Viral diseases
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0HSS, Amar-Singh
1Koh, Mia-Tuang
2Tan, Kah Kee
3Chan, Lee Gaik
4Zhou, Lynn
5Bouckenooghe, Alain
6Crevat, Denis
7Hutagalung, Yanee
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2Pascal-Francis
3Medline
4MEDLINE
5MEDLINE (Ovid)
6MEDLINE
7MEDLINE
8PubMed
9CrossRef
10Academic OneFile (A&I only)
11MEDLINE - Academic
12OpenAIRE (Open Access)
13OpenAIRE
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0HSS, Amar-Singh
1Koh, Mia-Tuang
2Tan, Kah Kee
3Chan, Lee Gaik
4Zhou, Lynn
5Bouckenooghe, Alain
6Crevat, Denis
7Hutagalung, Yanee
formatjournal
genrearticle
ristypeJOUR
atitleSafety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2–11 years in Malaysia: A randomized, placebo-controlled, Phase III study
jtitleVaccine
addtitleVaccine
date2013
risdate2013
volume31
issue49
spage5814
epage5821
pages5814-5821
issn0264-410X
eissn1873-2518
codenVACCDE
abstractHighlights • We evaluate a Phase III production lot of a candidate dengue vaccine (CYD-TDV). • CYD-TDV demonstrates a satisfactory safety profile in children. • CYD-TDV demonstrates a balanced immune response against all dengue virus serotypes.
copKidlington
pubElsevier Ltd
pmid24135573
doi10.1016/j.vaccine.2013.10.013
oafree_for_read